Literature DB >> 20732949

Gender-specific reduction of estrogen-sensitive small RNA, miR-30b, in subjects with schizophrenia.

Nikolaos Mellios1, Marzena Galdzicka, Edward Ginns, Stephen P Baker, Evgeny Rogaev, Jun Xu, Schahram Akbarian.   

Abstract

Estrogen signaling pathways affect cortical function and metabolism, are thought to play a role in the pathophysiology of schizophrenia, and exert neuroprotective effects in female subjects at risk. However, the molecular signatures of estrogen signaling in normal and diseased cerebral cortex remain largely unexplored. Expression of the estrogen-sensitive small RNA, microRNA-30b (miR-30b), was studied in 30 controls and 30 matched samples from subjects diagnosed with schizophrenia from prefrontal cortex (PFC), as well as in 23 samples from parietal cortex (12 controls and 11 schizophrenia cases). The majority of case and control samples were genotyped for an estrogen receptor α (Esr1) sequence variant (rs2234693) previously associated with genetic risk, and a subset of them were subjected to further analysis to determine expression of mature and precursor forms of miR-30b (pre/pri-miR-30b). Gender-dimorphic expression was also explored in mouse frontal cortex and hippocampus. A significant interaction between gender and diagnosis was discovered for changes in mature miR-30b levels, so that miR-30b expression was significantly reduced in the cerebral cortex of female but not male subjects with schizophrenia. In addition, disease-related changes in miR-30b expression in a subset of female subjects were further modulated by Esr1 genotype. Changes after antipsychotic drug exposure remained insignificant. These preliminary findings point to the possibility that disease-related changes in the expression of small noncoding RNAs such as miR-30b in schizophrenia could be influenced by gender and potentially regulated by estrogen signaling.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20732949      PMCID: PMC3329977          DOI: 10.1093/schbul/sbq091

Source DB:  PubMed          Journal:  Schizophr Bull        ISSN: 0586-7614            Impact factor:   9.306


  59 in total

1.  The MicroRNA miR-124 promotes neuronal differentiation by triggering brain-specific alternative pre-mRNA splicing.

Authors:  Eugene V Makeyev; Jiangwen Zhang; Monica A Carrasco; Tom Maniatis
Journal:  Mol Cell       Date:  2007-08-03       Impact factor: 17.970

2.  MicroRNAs and target site screening reveals a pre-microRNA-30e variant associated with schizophrenia.

Authors:  Yong Xu; Fei Li; Bo Zhang; Kerang Zhang; Fuquan Zhang; Xuezhu Huang; Ning Sun; Yan Ren; Manqiu Sui; Pozi Liu
Journal:  Schizophr Res       Date:  2010-03-27       Impact factor: 4.939

3.  Evidence for selective microRNAs and their effectors as common long-term targets for the actions of mood stabilizers.

Authors:  Rulun Zhou; Peixiong Yuan; Yun Wang; Joshua G Hunsberger; Abdel Elkahloun; Yanling Wei; Patricia Damschroder-Williams; Jing Du; Guang Chen; Husseini K Manji
Journal:  Neuropsychopharmacology       Date:  2008-08-13       Impact factor: 7.853

4.  An activity-regulated microRNA controls dendritic plasticity by down-regulating p250GAP.

Authors:  Gary A Wayman; Monika Davare; Hideaki Ando; Dale Fortin; Olga Varlamova; Hai-Ying M Cheng; Daniel Marks; Karl Obrietan; Thomas R Soderling; Richard H Goodman; Soren Impey
Journal:  Proc Natl Acad Sci U S A       Date:  2008-06-24       Impact factor: 11.205

5.  miR-206 Expression is down-regulated in estrogen receptor alpha-positive human breast cancer.

Authors:  Naoto Kondo; Tatsuya Toyama; Hiroshi Sugiura; Yoshitaka Fujii; Hiroko Yamashita
Journal:  Cancer Res       Date:  2008-07-01       Impact factor: 12.701

6.  Molecular determinants of dysregulated GABAergic gene expression in the prefrontal cortex of subjects with schizophrenia.

Authors:  Nikolaos Mellios; Hsien-Sung Huang; Stephen P Baker; Marzena Galdzicka; Edward Ginns; Schahram Akbarian
Journal:  Biol Psychiatry       Date:  2009-01-01       Impact factor: 13.382

7.  Normalization of microRNA expression levels in quantitative RT-PCR assays: identification of suitable reference RNA targets in normal and cancerous human solid tissues.

Authors:  Heidi J Peltier; Gary J Latham
Journal:  RNA       Date:  2008-03-28       Impact factor: 4.942

8.  Xenoestrogen-induced epigenetic repression of microRNA-9-3 in breast epithelial cells.

Authors:  Pei-Yin Hsu; Daniel E Deatherage; Benjamin A T Rodriguez; Sandya Liyanarachchi; Yu-I Weng; Tao Zuo; Joseph Liu; Alfred S L Cheng; Tim H-M Huang
Journal:  Cancer Res       Date:  2009-06-23       Impact factor: 12.701

9.  MicroRNA-219 modulates NMDA receptor-mediated neurobehavioral dysfunction.

Authors:  Jannet Kocerha; Mohammad Ali Faghihi; Miguel A Lopez-Toledano; Jia Huang; Amy J Ramsey; Marc G Caron; Nicole Sales; David Willoughby; Joacim Elmen; Henrik F Hansen; Henrik Orum; Sakari Kauppinen; Paul J Kenny; Claes Wahlestedt
Journal:  Proc Natl Acad Sci U S A       Date:  2009-02-05       Impact factor: 11.205

10.  Identification of microRNAs controlling human ovarian cell steroidogenesis via a genome-scale screen.

Authors:  Alexander V Sirotkin; Dmitriy Ovcharenko; Roland Grossmann; Marcela Lauková; Milos Mlyncek
Journal:  J Cell Physiol       Date:  2009-05       Impact factor: 6.384

View more
  35 in total

Review 1.  MicroRNAs in Schizophrenia: Implications for Synaptic Plasticity and Dopamine-Glutamate Interaction at the Postsynaptic Density. New Avenues for Antipsychotic Treatment Under a Theranostic Perspective.

Authors:  Andrea de Bartolomeis; Felice Iasevoli; Carmine Tomasetti; Elisabetta F Buonaguro
Journal:  Mol Neurobiol       Date:  2014-11-14       Impact factor: 5.590

Review 2.  Heterogeneity and individuality: microRNAs in mental disorders.

Authors:  Leif G Hommers; Katharina Domschke; Jürgen Deckert
Journal:  J Neural Transm (Vienna)       Date:  2014-11-14       Impact factor: 3.575

Review 3.  MicroRNAs in neuronal communication.

Authors:  Guilherme Shigueto Vilar Higa; Erica de Sousa; Lais Takata Walter; Erika Reime Kinjo; Rodrigo Ribeiro Resende; Alexandre Hiroaki Kihara
Journal:  Mol Neurobiol       Date:  2014-01-03       Impact factor: 5.590

4.  Regulatory role of microRNA-30b and plasminogen activator inhibitor-1 in the pathogenesis of cognitive impairment.

Authors:  Xiuqin Li; Yong Gao; Zhaoyun Meng; Cui Zhang; Qinde Qi
Journal:  Exp Ther Med       Date:  2016-03-15       Impact factor: 2.447

Review 5.  MicroRNAs and Child Neuropsychiatric Disorders: A Brief Review.

Authors:  Sujay Paul; Paula Roxana Reyes; Betsabé Sánchez Garza; Ashutosh Sharma
Journal:  Neurochem Res       Date:  2019-11-26       Impact factor: 3.996

Review 6.  An emerging role for microRNAs in sexually dimorphic neurobiological systems.

Authors:  Toni R Pak; Yathindar S Rao; Sarah A Prins; Natasha N Mott
Journal:  Pflugers Arch       Date:  2013-02-09       Impact factor: 3.657

Review 7.  Diagnostic and therapeutic potential of microRNAs in neuropsychiatric disorders: Past, present, and future.

Authors:  Begum Alural; Sermin Genc; Stephen J Haggarty
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2016-04-09       Impact factor: 5.067

8.  Analysis of miR-137 expression and rs1625579 in dorsolateral prefrontal cortex.

Authors:  Ilaria Guella; Adolfo Sequeira; Brandi Rollins; Linda Morgan; Federica Torri; Theo G M van Erp; Richard M Myers; Jack David Barchas; Alan F Schatzberg; Stanley J Watson; Huda Akil; William E Bunney; Steven G Potkin; Fabio Macciardi; Marquis P Vawter
Journal:  J Psychiatr Res       Date:  2013-06-17       Impact factor: 4.791

9.  Epigenetic mechanisms in schizophrenia and other psychotic disorders: a systematic review of empirical human findings.

Authors:  Lukasz Smigielski; Vinita Jagannath; Wulf Rössler; Susanne Walitza; Edna Grünblatt
Journal:  Mol Psychiatry       Date:  2020-01-06       Impact factor: 15.992

10.  MiR-30-regulated autophagy mediates angiotensin II-induced myocardial hypertrophy.

Authors:  Wei Pan; Yun Zhong; Chuanfang Cheng; Benrong Liu; Li Wang; Aiqun Li; Longgen Xiong; Shiming Liu
Journal:  PLoS One       Date:  2013-01-09       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.